Oncology

Layoffs
Biotech

Sensei lays off 46% of staff, closes site to fund cancer trial

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to take its immune checkpoint inhibitor though phase 2.
James Waldron Nov 14, 2024 9:38am
flare sun light reflection

Roche sparks $1.8B-plus discovery deal with Flare Therapeutics

Nov 12, 2024 7:00am
embryonic stem cells

MD Anderson launches cell therapy institute with $80M

Nov 11, 2024 4:20pm
Wrapped gift basket on a blue background

Medidata meshes services into oncology and vaccine trial bundles

Nov 5, 2024 3:40pm
team funding workforce workforce reductions cash runway

Sana strips back cancer, CNS programs while warning of layoffs

Nov 5, 2024 7:05am
kidney cancer renal cell carcinoma tumor

Arcus drops promising data on HIF-2a candidate in kidney cancer

Oct 24, 2024 2:48pm
More News

AvenCell bags $112M to flick 'switchable' CAR-Ts in the clinic

Oct 22, 2024 6:00am

FDA puts partial hold on BioNTech-OncoC4 phase 3 trial

Oct 18, 2024 12:55pm

Novartis pays Baiyu $70M, with $1.1B chaser, for cancer prospect

Oct 17, 2024 8:17am

Ocean Biomedical pens $32M pact for Polish YKL-40 inhibitors

Oct 15, 2024 10:05am